Development of small molecule inhibitors targeting TGF-beta ligand and receptor: Structures, mechanism, preclinical studies and clinical usage
Transforming growth factor-beta (TGF-beta) is a member of a superfamily of pleiotropic proteins that regulate multiple cellular processes such as growth, development and differentiation. Following binding to type I and II TGF-beta serine/threonine kinase receptors, TGF-beta activates downstream sign...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Elsevier
2020
|
| Subjects: | |
| Online Access: | http://eprints.um.edu.my/36800/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Transforming growth factor-beta (TGF-beta) is a member of a superfamily of pleiotropic proteins that regulate multiple cellular processes such as growth, development and differentiation. Following binding to type I and II TGF-beta serine/threonine kinase receptors, TGF-beta activates downstream signaling cascades involving both SMAD-dependent and -independent pathways. Aberrant TGF-beta signaling is associated with a variety of diseases, such as fibrosis, cardiovascular disease and cancer. Hence, the TGF-beta signaling pathway is recognized as a potential drug target. Various organic molecules have been designed and developed as TGF-beta signaling pathway inhibitors and they function by either down-regulating the expression of TGF-beta or by inhibiting the kinase activities of the TGF-beta receptors. In this review, we discuss the current status of research regarding organic molecules as TGF-beta inhibitors, focusing on the biological functions and the binding poses of compounds that are in the market or in the clinical or pre-clinical phases of development. (c) 2020 Elsevier Masson SAS. All rights reserved. |
|---|